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Summary Bronchial artery embolization (BAE) is the treatment of choice in the
majority of patients with severe hemoptysis. However, this procedure may be
unavailable and even fail or be counterindicated in 4–13% of cases. In these cases, the
efficacy of fibrinogen–thrombin (FT) instilled endoscopically as treatment for massive
hemoptysis was assessed. Between August 1993 and February 1996 a prospective
clinical study was performed. FT instillation was indicated in all patients with severe
hemoptysis (4150ml/12 h) in whom BAE had failed, was counterindicated or not
available. FTwas instilled endoscopically. Patients were followed up until June 2001.
Eleven of 101 patients (11%) with hemoptysis 4150ml/12 h in whom BAE was not
possible or proved ineffective were included. The severe hemoptysis was controlled
immediately in all cases. During the follow-up period (mean: 39.4 months), early
relapse of the severe hemoptysis occurred in two patients (18%) and a long- time
relapse in one. Mean procedure duration was 3min and no attributable complications
were observed in any case. In conclusion, these results suggest that topical treatment
with FT could be considered in the initial endoscopic evaluation of patients with
severe hemoptysis while awaiting BAE or surgery, or as alternative treatment to
arterial embolization when the latter is not available, has proved ineffective or is
counterindicated.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
Severe hemoptysis constitutes a medical emer-
gency, with mortality between 7 and 10%.1–4 The
most frequent causes of death are asphyxia and
intractable hypoxemia due to the inundation of
blood within alveoli.5–7 Because of the unpredict-
able course of severe hemoptysis, maintenance of
airway patency and control of the bleeding are the
primary immediate goals.1–7
The ideal time for bronchoscopy is controversial.
Whereas delayed bronchoscopy, within 24–48 h of
admission, is preferred in stable patients before
performing computed tomography8 in severe he-
moptysis, bronchoscopy is the initial procedure of
choice for most authors,6–10 particularly during
active bleeding, since it permits the bleeding lung
to be displaced to one side, the exact bleeding
point to be located, and to be obtained an etiologic
diagnosis in some cases. Furthermore, the exact
location of the bleeding point will be of inestimable
value as a guide for applying topical therapeutic
measures, possible surgical treatment or bronchial
artery embolization (BAE) that may be urgently
indicated if the bleeding persists or worsens.
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Morbidity and mortality are high when urgent
surgery is performed;5,6,10–11 thus, BAE, in recent
years, has become the treatment of choice in
severe hemoptysis as a palliative procedure pre-
paring the patient for elective surgery of localized
disease or continued antimicrobial therapy if
indicated.12–17 In patients deemed too ill to under-
go elective surgery, BAE may be repeated success-
fully for recurrent hemoptysis. However, this
technique is not always available in emergencies
in all hospital centers; even when available, it is
ineffective,18–21 not possible to perform or coun-
terindicated in 4–13% of cases.22 In such situations,
additional bronchoscopic techniques to tamponade
the bleeding bronchial segment including thrombin
or fibrinogen–thrombin (FT) combination,23–24
Fogarthy balloon-tipped,25–26 right-heart balloon
catheters,27 endobronchial electrosurgery or laser
therapy28 may be helpful in preserving gas
exchange to a great extent.
The aim of the present study was to assess the
efficacy of endoscopic FT administration in the
short-, medium- and long-term control of severe
hemoptysis in patients in whom BAE could not be
performed for the reasons stated above.
Materials and methods
Study population
From August 1993 to February 1996, a prospective
study was conducted using FT instillation via
fiberoptic bronchoscopy (FOB) in all patients with
severe hemoptsis (150ml/12 h) in whom BAE could
not be performed either because of unavailability,
ineffectiveness (in case of early relapse after the
first embolization attempt or if no anomalous
bronchial artery branch is found) or because it
was counterindicated (anticoagulant treatment,
pregnancy or previous vascular injury).
Bronchoscopy technique
FOB was performed in all cases by expert bronch-
oscopists trained in performing the technique,
using Pentax 18X or 19TX (Asahi Optical Co. Ltd.,
Tokyo, Japan) bronchoscopes. Fifteen minutes
before insertion, 0.5mg of atropine was injected
subcutaneously. The upper airway was anesthetized
with 5ml of 1% lidocaine solution administered
orally by nebulization, and additional small quan-
tities of lidocaine were instilled through the
bronchoscope as required to control coughing.29 In
patients with assisted mechanical ventilation and
endotracheal intubation, the FOB was inserted
through the same. Oxygen saturation was mon-
itored in all patients by digital pulsioxymetry
(Minolta Pulsox TS-7s, Japan), together with
cardiac frequency and ECG registry (Cardiolife
TEC-7200s, NIHON KOHDEN Corp., Japan). Non-
intubated patients received oxygen supplements by
nasal probe or by mouth. Following FOB insertion,
remains of blood were carefully aspirated from the
airways. Once the bleeding site was identified,
local hemostasis measures were applied using
instillation via the FOB aspiration channel of cold
sterile 0.9% saline solution, epinephrine solution
(diluted at 1:20,000 in cold sterile 0.9% saline
solution) or by collapse of the bleeding bronchial
orifice by applying continuous aspiration with the
FOB.30,31 The FT solution was instilled immediately
after these measures and after drying of the airway
with oxygen, administered directly through the FOB
channel (connecting an O2 probe directly to the
suction channel, at a flow of 3–4 l/min and a
pressure of 5 bar). Endoscopic revision of the whole
bronchial tree was made once the bleeding had
been controlled. Samples of bronchial washings
were obtained in all cases for cytology study and
Micobacterium tuberculosis and aerobic bacteria
identification.
Fibrinogen–thrombin instillation
The FTsolution used (Tissucols, Baxter AG, Vienna)
consisted of two vials. The first contained a
fibrinogen solution (70–110mg/ml), fibronectin
(2–9mg/ml), factor XIII (10–50U/ml), plasminogen
(0.04–0.12mg/ml), and aprotin (3000 KIU/ml). The
second contained a Cl2 Ca solution (40mmol/L) and
human thrombin (500 IU/ml). The two components
were instilled simultaneously into the bleeding
bronchial orifice using syringes connected to a
double-syringe system (Duplojects, Baxter AG,
Vienna) and a double-channel, 180 cm long,
0.17 cm external diameter catheter (Duplocaths
180, Baxter AG, Vienna). This catheter was passed
through the bronchoscope channel and placed
inside the bleeding bronchial segment or sub-
segment.
BAE and surgery
Within 5 days post-FT instillation, BAE was recon-
sidered if it had previously been counterindicated
or was not available. BAE or lung surgery was
considered if episodes of severe hemoptysis
recurred after FT instillation.
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Follow-up
After discharge, all patients were followed up
every 6 months on an outpatient basis, or by
telephone if that were not possible, until June
2001.
Therapy was considered ineffective if hemoptysis
recurred within 6 h after treatment. Short-, mid-
and long-term recurrent hemoptysis was defined as
a further hemoptysis episode occurring between 6 h
and 14 days, 14 days and 6 months and more than 6
months, respectively, post-FT treatment.
Results
During the inclusion period, hemoptysis of any
extent was the indication for FOB in 360 of 1234
(29.2%) examinations; of these, hemoptysis was
severe (4150ml/12 h) in 101 cases (27.8%). FT
administration was indicated in 11 of these 101
(11.11%) patients (7 men; mean age7SD 55.1714
years; range: 15–88) in whom BAE could not be
performed because it was normal in one case
(patient 1), counterindicated in 3 cases (patients
4, 6 and 9), not available in 3 cases (patients 3, 5
and 7) and failed in the other 4 cases. Follow-up
ranged from 7 days to 74 months (mean: 39.4
months). Clinical characteristics of the patients,
indications for FT treatment, hemoptysis etiology,
follow-up period and evolution are shown in
Table 1.
FOB with FT instillation was indicated from the
Emergency Room in all but three cases (patients 1,
2 and 7) in which it was performed at 48, 72 and
98 h, respectively. It was carried out after admis-
sion because of hemoptysis persistence following
FOB with local hemostasis (cold normal sterile
saline solution, epinephrine instillation and bron-
chial occlusion) and the impossibility of performing
BAE (normal bronchial arteriogram in the first,
failure of the procedure in the second and unavail-
ability in the third).
The FT dose required was 2ml in all but three
patients, who required two instillations of 2ml
owing to two different bleeding points (patients 1
and 11) and technical failure in the third (patient
4). The administration of FT extended the FOB
examination by a mean of 3min (range: 2–7min),
with an additional cost of $ 131 per 2ml of solution
(150.3 h).
FT instillation immediately controlled the active
bronchial bleeding in all patients. However, in the
short term, severe hemoptysis relapses were
observed in two patients (18%) (6 h post-FT treat-
ment in patient 11, and 3 days post-FT treatment in
patient 10). Both were treated with BAE, and
patient 11 also with left-pneumonectomy 5 days
post-embolization, owing to severe hemoptysis. In
patient 6, in whom BAE had initially been counter-
indicated owing to pharmacological anticoagula-
tion, the procedure was applied on the decision of
the attending physician 3 days post-FT treatment
once the coagulation had been corrected. In the
remaining 8 patients, long-term severe hemoptysis
relapse was observed in only one (patient 9), 12
months post-FT instillation. Long- term hemoptysis
control was 70% (7/10), with the exclusion of
patient 6.
FOB examination could be completed in all
patients, with no complications that required its
suspension; however, in one patient (No. 4) oxygen
desaturations o75% were observed and corrected
with 100% oxygen administration using a probe
connected directly to the FOB aspiration channel.
Bronchial bleeding during the examination was
o50ml in the majority of patients, except in
patients 1, 6, and 10 in whom bronchial bleeding
was quantified as 150–200ml.
Cytological and bacteriological study of the
bronchial washings provided specific diagnosis in
three patients: squamous carcinoma (patient 4),
pulmonary tuberculosis (patient 11) and Pseudo-
mona aeruginosa infection (4106 cfu/ml) in a
patient with diffuse bronchiectasis (patient 1).
Discussion
In our study the use of FT permitted immediate
control of severe hemoptysis in all cases, as well as
short-term control in 82% and long-term control in
70%.
Different types of substances have been used in
the topical treatment of severe hemoptysis, such as
irrigation with ice saline solution5,6,11 and combi-
nation of saline solution and epinephrine,30,31
which are effective in controlling minor bleedings
and those occurring after transbronchial lung
biopsy, but are not usually a satisfactory treatment
of more extensive larger bleedings. Substances that
favor or reproduce physiological hemostatic me-
chanisms such as Bosmins, thrombin,32 FT23,24 and
Reptilases 33 have been also used, with acceptable
success rates, but a greater number of cases is
lacking. Recently, n-butyl cyanoacrylate34 a bio-
compatible glue that solidifies quickly, has been
used in six patients with prolonged hemoptysis
(200–1000ml/7–45 days), not always 4150ml/
12 h, with only one recurrence during the follow-
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up period. Unlike the substances mentioned above,
cyanoacrylate produces post-procedure cough and
is expectorated gradually in the days after instilla-
tion.
FT has been widely and successfully used in
surgery with multiple bleeding points or when the
use of electrical cauterization, sutures or staples
was not advisable.35 After including the patients of
the present study (Table 2), the local application
via FOB of FT in the treatment of massive
hemoptysis has been described in 23 patients.
Immediate control of the hemoptysis was achieved
in 22 of these 23 cases (95%) and 16 of the 23 (69%)
patients did not present relapses during the follow-
up period, which varied between 6 h and 74 months
(mean 7SD, 39.47727.37 months).
In the initial study by Tsukamoto et al.,23 the
instillation of FT was performed at different times
using a thrombin solution of 1000 IU/ml which
favors the rapid formation of the fibrin clot.
Immediate control of hemoptysis was achieved
with this technique in all cases; however, 3 of the
9 patients presented recurrences between the
following 24 h and 14 days. Modifications in the
administration technique were introduced in the
present study and in that conducted by Bense24
such as simultaneous instillation at the bleeding
point of equal volumes of fibrinogen and
thrombin using the Duplojects system; use of a
thrombin solution that delays fibrin clot formation
for up to 10 s, giving time for the mixture of
fibrinogen and thrombin to penetrate distally
towards the bleeding source from the point they
were released; and addition to the solution of
Factor XIII and aprotinin, whose actions consist of
stabilizing the fibrin clot formed and delaying the
fibrinolytic action of plasma for up to 10 days,
respectively.
Although the fibrin glue instillation technique is
simple, it may not prove effective when the patient
bleeds copiously. In these cases, previous local
hemostatic techniques are required: ice saline
solution, combination of saline solution and epi-
nephrine and airway collapse, which permit suffi-
cient momentary bleeding control to ensure
instillation of the fibrin glue in the correct site.
Furthermore, airway drying with direct oxygen
administration through the FOB channel permitted
better adhesion of the fibrin glue to the bleeding
bronchial wall. The fact that fibrinogen is a plasma
derivate obtained from blood donors is the main
drawback to its use; however, the control and
manufacturing processes involved in its supply
ensure viral inactivation;36 no cases of disease
transmission have been described despite its
extensive use in surgery.
In conclusion, the present study suggests that
local instillation of FT in the bronchial tree is a
simple, economical and efficacious technique as a
palliative procedure in the immediate and short-
term control of severe hemoptysis. Its routine
use during FOB evaluation of patients with severe
hemoptysis and in whom active bleeding is
demonstrated could be considered prior to BAE.
It could help to ensure better hemoptysis
control during BAE and, particularly, when the
latter proves ineffective or must be postponed.
Although the results of this study also show
acceptable mid- and long-term hemoptysis control,
the scant number of patients and study design
do not support its routine use in treatment for
severe hemoptysis as an alternative to BAE.
However, FT instillation could be considered when
this technique is unavailable, fails or is counter-
indicated.
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Table 2 Efficacy of FT endobronchial infusion therapy in severe hemoptysis.
Author Patients (no.) Agent Efficacyn Follow-up months (mean) Recurrent hemoptysisw
Tsukamoto (1989) 9 FT 9 11–60 3w
Bense (1990) 3 FT (Tissucols, 3 2–36(16) Iw
1ml)
De Gratia (2003)
11 FT (Tissucols, 11 0.23–72 (39.4) 2w
2ml) Iz
nImmediate control of active bronchial bleeding.
wShort-term recurrent hemoptysis (o14 days post-FT treatment).
zLong-term recurrent hemoptysis (4 6 months post-FT treatment).
794 J. de Gracia et al.
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